Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 6, Pages 711–720
http://dx.doi.org/10.1155/2013/478303
Review Article

Mast Cells as a Potential Prognostic Marker in Prostate Cancer

1Department of Urology, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
2Department of Pathology, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
3Department of Pathology, School of Medicine, University of Rijeka, Brace Branchetta Street No. 20, 51 000 Rijeka, Croatia
4Laboratory of Molecular Gastroenterology, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy

Received 30 June 2013; Accepted 7 October 2013

Academic Editor: Maddalena Ruggieri

Copyright © 2013 Gianluigi Taverna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [15 citations]

The following is the list of published articles that have cited the current article.

  • Yanbo Liu, Xiaohui Zhao, Xuemei Sun, Yongmei Li, Zhenjiang Wang, Jing Jiang, Huiming Han, Weigao Shen, Chris J. Corrigan, and Ying Sun, “Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia,” The Prostate, 2015. View at Publisher · View at Google Scholar
  • Gianluigi Taverna, Elisa Pedretti, Giuseppe Di Caro, Elena Monica Borroni, Federica Marchesi, and Fabio Grizzi, “Inflammation and prostate cancer: friends or foe?,” Inflammation Research, 2015. View at Publisher · View at Google Scholar
  • Qiang Dang, Lei Li, Hongjun Xie, Dalin He, Jiaqi Chen, Wenbing Song, Luke S. Chang, Hong-Chiang Chang, Shuyuan Yeh, and Chawnshang Chang, “Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells→androgen receptor (AR)→miRNA32 signals,” Molecular Oncology, 2015. View at Publisher · View at Google Scholar
  • Amy Strasner, and Michael Karin, “Immune infiltration and prostate cancer,” Frontiers in Oncology, vol. 5, no. MAY, 2015. View at Publisher · View at Google Scholar
  • Maryam Sarbishegi, Ozra Khajavi, and Mohammad Reza Arab, “Withania coagulans Extract Induces Cell Apoptosis and Inhibits COX-2 Expression in a Rat Model of Benign Prostatic Hyperplasia,” Nephro-Urology Monthly, vol. Inpress, no. Inpress, 2016. View at Publisher · View at Google Scholar
  • Alessandro Sciarra, Alessandro Gentilucci, Stefano Salciccia, Federico Pierella, Flavio Del Bianco, Vincenzo Gentile, Ida Silvestri, and Susanna Cattarino, “Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review,” Journal of Inflammation, vol. 13, no. 1, 2016. View at Publisher · View at Google Scholar
  • Heidi A. Hempel, Nathan S. Cuka, Ibrahim Kulac, John R. Barber, Toby C. Cornish, Elizabeth A. Platz, Angelo M. De Marzo, and Karen S. Sfanos, “Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence,” The Prostate, vol. 77, no. 4, pp. 412–424, 2016. View at Publisher · View at Google Scholar
  • Stephen L. Shiao, Gina Chia-Yi Chu, and Leland W.K. Chung, “Regulation of prostate cancer progression by the tumor microenvironment,” Cancer Letters, 2016. View at Publisher · View at Google Scholar
  • Katarzyna Miłek, Aleksandra Strzępek, Magdalena Białas, Tomasz Gołąbek, Krzysztof Okoń, Karolina Kaczmarczyk-Sekuła, Grzegorz Dyduch, Joanna Szpor, Tomasz Szopiński, and Piotr Chłosta, “Mast cells influence neoangiogenesis in prostatic cancer independently of erg status,” Polish Journal of Pathology, vol. 67, no. 3, pp. 244–249, 2016. View at Publisher · View at Google Scholar
  • Mozhdeh Foroozan, Raheleh Roudi, Maryam Abolhasani, Elmira Gheytanchi, and Mitra Mehrazma, “Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma,” Pathology - Research and Practice, 2017. View at Publisher · View at Google Scholar
  • Božo Krušlin, Davor Tomas, Tihana Džombeta, Marija Milković-Periša, and Monika Ulamec, “Inflammation in Prostatic Hyperplasia and Carcinoma—Basic Scientific Approach,” Frontiers in Oncology, vol. 7, 2017. View at Publisher · View at Google Scholar
  • Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, and Fred Saad, “The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements,” Biomarkers in Cancer, vol. 8s2, pp. BIC.S31802, 2017. View at Publisher · View at Google Scholar
  • Bruno Felix-Patrício, Alexandre F. Miranda, Jorge L. Medeiros Jr., Carla B. M. Gallo, Bianca M. Gregório, Diogo B. de Souza, Waldemar S. Costa, and Francisco J. B. Sampaio, “The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis,” International braz j urol, vol. 43, no. 5, pp. 957–965, 2017. View at Publisher · View at Google Scholar
  • Alison M. Mondul, Jiaqi Huang, Stephanie J. Weinstein, Edward D. Karoly, Joshua N. Sampson, and Demetrius Albanes, “Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor,” Oncotarget, vol. 8, no. 28, pp. 45190–45199, 2017. View at Publisher · View at Google Scholar
  • Bianca Facchim Gonçalves, Silvana Gisele Pegorin de Campos, Wagner José Fávaro, Joyce Zalotti Brandt, Cristiane Figueiredo Pinho, Luis Antônio Justulin, Sebastião Roberto Taboga, and Wellerson Rodrigo Scarano, “Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats,” Hormones and Cancer, 2018. View at Publisher · View at Google Scholar